10-Q: Candel Therapeutics Reports Net Income for Q1 2025, Advances Clinical Programs

Candel Therapeutics reports a net income of $7.4 million for Q1 2025, driven by a change in the fair value of warrant liability, while continuing to advance its clinical-stage viral immunotherapies.

Summary

• Candel Therapeutics, a clinical-stage biopharmaceutical company, reported a net income of $7.4 million for the three months ended March 31, 2025, compared to a net loss of $8.2 million for the same period in 2024.
• The company's operating expenses totaled $8.1 million, with research and development expenses at $4.0 million and general and administrative expenses at $4.1 million.
• The change in fair value of warrant liability significantly impacted the net income, contributing $14.9 million.
• Candel Therapeutics is focused on developing off-the-shelf viral immunotherapies, with its lead product candidate, CAN-2409, in a pivotal phase 3 clinical trial for prostate cancer.
• The company also announced positive topline data from the phase 3 clinical trial of CAN-2409 in December 2024, demonstrating a statistically significant improvement in disease-free survival.
• Another product candidate, CAN-3110, is being evaluated in a phase 1b clinical trial for recurrent high-grade glioma.
• The company's cash and cash equivalents were $92.2 million as of March 31, 2025, which is expected to fund operations into the first quarter of 2027.
• Candel Therapeutics anticipates submitting a biologics license application for CAN-2409 in the fourth quarter of 2026.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with improved financial results and promising clinical trial data, suggesting a favorable trajectory for the company.

Positives

• The company achieved net income in Q1 2025, indicating improved financial performance.
• The company has sufficient cash to fund operations into Q1 2027.
• CAN-2409 demonstrated positive results in phase 3 prostate cancer trial, phase 2 NSCLC trial, and phase 2 pancreatic cancer trial.
• CAN-3110 continues to show promise in recurrent high-grade glioma trials.
• The company has received Fast Track and Orphan Drug Designations for CAN-2409 and CAN-3110, potentially expediting regulatory review.

Negatives

• The company has a limited operating history and has not generated any revenue from product sales.
• The company has incurred significant operating losses since inception and expects to continue to incur losses for the foreseeable future.
• The company is dependent on the success of CAN-2409, CAN-3110 and any other product candidates that it advances into the clinic.
• The company's product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval, if at all.

Risks

• The company will need to raise substantial additional funding, and if unable to do so, may have to delay, reduce, or eliminate some of its product development programs.
• Clinical trials may fail to demonstrate adequately the safety and efficacy of product candidates.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• The company is subject to numerous environmental, health and safety laws and regulations, and failure to comply could result in fines or penalties.
• The company is subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as import and export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition, results of operations, stock price and prospects.

Future Outlook

Candel Therapeutics expects its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2027 and anticipates submitting a biologics license application for CAN-2409 in the fourth quarter of 2026.

Management Comments

• Based on these results, we anticipate submitting a biologics license application for CAN-2409 in the fourth quarter of 2026.
• Based on these positive findings, the Company will advance the enabling work for a potentially registrational clinical trial of CAN-2409 in non-squamous NSCLC with progressive disease despite ICI.
• Based on these promising findings, the Company will advance the enabling work for a potentially registrational clinical trial of CAN-2409 in borderline resectable PDAC.

Industry Context

Candel Therapeutics is operating in the competitive biopharmaceutical industry, specifically in the immuno-oncology and viral immunotherapy space, competing with major pharmaceutical companies and other biotechnology firms developing cancer treatments.

Comparison to Industry Standards

• The reported median overall survival (mOS) of 24.5 months in NSCLC patients with an inadequate response to immune checkpoint inhibitor (ICI) treatment (Cohort 1+2, n=46) is longer than the 9.8-11.8 months of survival reported in published literature in a similar patient population receiving standard of care of docetaxel chemotherapy (Paz-Ares LG et al, J Clin Oncol 2024;42:2860-2872 ; Ahn MJ et al, J Clin Onc 2024;43:260-272).
• The estimated median overall survival after enrollment was 31.4 months in the CAN-2409 group versus only 12.5 months in the control group in borderline resectable PDAC.

Management Changes

Legal Proceedings

• From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business.

Related Party Transactions

• Stockholders of the Company own 49.5 % of the voting stock of Ventagen, including 47 % by the Company's founders who are currently significant stockholders of the Company, and trusts for the benefit of their children.

Stakeholder Impact

• Positive clinical trial results and improved financial performance could increase shareholder value.
• Advancement of product candidates may lead to new treatment options for patients.
• Continued operations and potential commercialization could create job opportunities.

Next Steps

• Advance the enabling work for a potentially registrational clinical trial of CAN-2409 in non-squamous NSCLC with progressive disease despite ICI.
• Advance the enabling work for a potentially registrational clinical trial of CAN-2409 in borderline resectable PDAC.
• Present initial median overall survival data for the repeat dosing cohort in the fourth quarter of 2025.
• Submit a biologics license application for CAN-2409 in the fourth quarter of 2026.

Key Dates

Keywords

CAN-2409, CAN-3110, viral immunotherapy, clinical trials, prostate cancer, NSCLC, PDAC, high-grade glioma, biopharmaceutical, regulatory approval